Oriol Mirallas, Medical Oncology Specialist at Vall d’Hebron Institute of Oncology, shared a post on X:
“Drug Development
SYNC-T Therapy (image guided cryolisis + infusion of SV-102 (fixed dose PD1, CTLA4, CD40 an TLR9) for mCRPC
– Fever and hematuria
– 87% with 8 CR
– Only 15 patientsDr. Tong.”
Read OncoDaily’s Special Articles about ASCO 2025:
Highlights from ASCO 2025 Day 1
Highlights from ASCO 2025 Day 2
